HR19042 capsule
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary IgA Nephropathy
Conditions
Primary IgA Nephropathy
Trial Timeline
Jul 1, 2021 → Jul 27, 2021
NCT ID
NCT04887532About HR19042 capsule
HR19042 capsule is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Primary IgA Nephropathy. The current trial status is completed. This product is registered under clinical trial identifier NCT04887532. Target conditions include Primary IgA Nephropathy.
What happened to similar drugs?
20 of 20 similar drugs in Primary IgA Nephropathy were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04887532 | Phase 1 | Completed |
Competing Products
20 competing products in Primary IgA Nephropathy